Daily Data as of 2/2/2023
| Closing Market Price | $14.86 |
| NAV | $16.91 |
| Premium/Discount | -12.12% |
| Daily Volume | 116,613 |
| Net Assets | $438,506,771 |
| Common Shares Outstanding | 25,931,802 |
| Percent Leveraged | N/A |
| 52 Week Average Premium/Discount | -7.84% |
| 52 Week High/Low Market Price | $ |
| 52 Week High/Low Market NAV | $ |
Distribution Information
| Current Distribution Rate | 8.73% |
| Quarterly Dividend Per Share | $0.3100 |
| Ex-Dividend Date | November 23, 2022 |
| Payable Date | December 30, 2022 |
Complete listing of historical distributions ▶
Current quarter’s distribution per share annualized, plus excise distribution, divided by the December 30, 2022 market price per share. The Fund’s fourth quarter 2022 distributions were estimated to be comprised of return-of-capital. The distribution rate alone is not indicative of Fund performance. The character of the current distributions was estimated and disclosed in a Section 19(a) Notice located under the “Investor Information” section of the Fund’s website. Please note that the distribution classifications are preliminary and certain distributions may be re-classified at year end. Please refer to year-end tax documents for the final classifications of the Fund’s distributions for a given year.
1 This excise distribution represents a one-time payment to satisfy annual tax distribution requirements.
ANNUAL DATA
| Fiscal Year-End | 9/30 |
| Portfolio Manager | Tekla Capital Management |
| Shareholder Servicing Agent | Destra Capital Advisors |
HQL Fact Card
Investment Objective
Tekla Life Sciences Investors ("HQL") is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQL. HQL primarily invests in the life sciences (including biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies), agriculture and environmental management industries. The Fund's objective is to provide long-term capital appreciation through investments in companies in the life sciences industry believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. Management believes this provides a unique opportunity not usually available to mutual fund investors.
